The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Open accessAbstract
Significance: Cancer immune evasion is well described. In some cases, this may be overcome by enhancing T-cell responses. We show that despite the presence of antitumor T cells, immunotherapeutic antibodies are ineffective in a murine pancreatic cancer model recapitulating the human disease. Removing the carcinoma-associated fibroblast (CAF) expressing fibroblast activation protein (FAP) from tumors permitted immune control of tumor growth and uncovered the efficacy of these immunotherapeutic antibodies. FAP + CAFs are the only tumoral source of chemokine (C-X-C motif) ligand 12 (CXCL12), and administering AMD3100, an inhibitor of chemokine (C-X-C motif) receptor 4, a CXCL12 receptor, also revealed the antitumor effects of an immunotherapeutic antibody and greatly diminished cancer cells. These findings may have wide clinical relevance because FAP + cells are found in almost all human adenocarcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“targeting CXCL12 signalling could be considered to be targeting CAFs as they are the major source of the chemokine in many tumours121.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“most studies have suggested an immunosuppressive role of CAFs121”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
In the citing paper
“the transcriptional profiles of apCAFs overlap with mesothelial cells150, and based on lineage tracing studies in mice have been postulated to derive from a mesothelial origin145”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [150]
In the citing paper
“They can further differentiate into myofibroblasts that express α-smooth muscle actin232.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [232]
In the citing paper
“fibroblast activation protein (FAP)+ CAFs inhibited anti-tumor function of T cells in gastric cancer and pancreatic cancer and targeting these FAP+ subtypes enhanced tumor response to ICB (Feig et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Feig et al., 2013
In the citing paper
“Moreover, CAF depletion using diphtheria toxin‐based immunotherapy reduced cancer growth by increasing CD8+ Teff‐cell infiltration to the TME [102].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Cited by
Sorted by citations
Items 701–800 of 1,000
Fibroblasts as Turned Agents in Cancer Progression
Wieder, R. (2023) · Cancers · doi:10.3390/cancers15072014 · Cited by 55
Epigenetic regulation of cancer-associated fibroblast heterogeneity
Kehrberg, R. J., Bhyravbhatla, N., Batra, S. K., & Sushil Kumar, K. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188901 · Cited by 57
Clinical immunotherapy in pancreatic cancer
Ye, X., Yu, Y., Zheng, X., & Ma, H. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03632-6 · Cited by 54
A collagenase nanogel backpack improves CAR-T cell therapy outcomes in pancreatic cancer
Zhao, Z., Li, Q., Qu, C., Jiang, Z., Jia, G., Lan, G., & Luan, Y. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01924-1 · Cited by 61
Fibroblasts, an inconspicuous but essential player in colon cancer development and progression
Mukaida, N., & Sasaki, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i23.5301 · Cited by 54
O’Hara, M. H., Messersmith, W. A., Kindler, H. L., Zhang, W., Pitou, C., Szpurka, A. M., Wang, D., Peng, S.-B., Vangerow, B., Khan, A. A., et al. (2020) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2019.0018 · Cited by 52
Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
Schmiechen, Z. C., & Stromnes, I. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613815 · Cited by 56
Cancer-Associated Fibroblasts: Implications for Cancer Therapy
Maia, A. R. R., & Wiemann, S. (2021) · Cancers · doi:10.3390/cancers13143526 · Cited by 58
Ansardamavandi, A., & Tafazzoli‐Shadpour, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119103 · Cited by 53
Cancer-Associated Fibroblast Functions as a Road-Block in Cancer Therapy
De, P. K., Aske, J. C., & Dey, N. (2021) · Cancers · doi:10.3390/cancers13205246 · Cited by 54
Zhao, L., Chen, J., Pang, Y., Fang, J., Fu, K., Meng, L., Zhang, X., Guo, Z., Wu, H., Sun, L., et al. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00424 · Cited by 53
Zhao, R., Sukocheva, O. A., Tse, E., Неганова, М. Е., Aleksandrova, Y. R., Zheng, Y., Gu, H., Zhao, D., Madhunapantula, S. V., Zhu, X., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01743-2 · Cited by 55
Torphy, R. J., Schulick, R. D., & Zhu, Y. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23179 · Cited by 54
Chronic Pancreatitis and the Development of Pancreatic Cancer
Kandikattu, H. K., Venkateshaiah, S. U., & Mishra, A. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200423095700 · Cited by 53
Piper, M., Mueller, A. C., & Karam, S. D. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23205 · Cited by 52
Zubair, H., Khan, M. A., Anand, S., Srivastava, S. K., Singh, S., & Singh, A. P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.009 · Cited by 53
Ambrosetti, D., Coutts, M., Paoli, C., Durand, M., Borchiellini, D., Montemagno, C., Rastoin, O., Borderie, A., Grépin, R., Rioux-Leclercq, N. C., et al. (2021) · British Journal of Urology · doi:10.1111/bju.15506 · Cited by 59
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions
Jenkins, B. H., Buckingham, J. F., Hanley, C. J., & Thomas, G. J. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108231 · Cited by 56
Ke, B.-J., Abdurahiman, S., Biscu, F., Zanella, G., Dragoni, G., Santhosh, S., Simone, V. D., Zouzaf, A., van Baarle, L., Stakenborg, M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173835 · Cited by 56
Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment
Arina, A., Corrales, L. P., & Bronte, V. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.01.002 · Cited by 52
Improving homing in T cell therapy
Vignali, D., & Kallikourdis, M. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.009 · Cited by 51
Fu, R., Zhang, Y., Li, H., Lv, W., Zhao, L., Guo, Q., Lu, T., Weiss, S. J., Li, Z., & Wu, Z. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14351 · Cited by 51
CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC)
Wald, O. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7100303 · Cited by 52
Immunotherapy of pancreatic cancer
Sunami, Y., & Kleeff, J. H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.03.006 · Cited by 52
T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting
Hanley, C. J., & Thomas, G. J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-1020-6 · Cited by 56
Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
Buqué, A., Bloy, N., Aranda, F., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Tartour, É., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149674 · Cited by 50
CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells
Fortunato, O., Belisario, D. C., Compagno, M., Giovinazzo, F., Bracci, C., Pastorino, U., Horenstein, A. L., Malavasi, F., Ferracini, R., Scala, S., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02168 · Cited by 49
Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance
Deng, D., Patel, R. H., Chiang, C.-Y., & Hou, P. (2022) · Cells · doi:10.3390/cells11192952 · Cited by 53
Verona, F., Bella, S. D., Schirano, R., Manfredi, C., Angeloro, F., Bozzari, G., Todaro, M., Giannini, G., Stassi, G., & Veschi, V. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529847 · Cited by 52
Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer
Zhang, J., Wolfgang, C. L., & Zheng, L. (2018) · Cancers · doi:10.3390/cancers10020039 · Cited by 52
Zhang, Y., Ware, M. B., Zaidi, M. Y., Ruggieri, A. N., Olson, B. M., Komar, H. M., Farren, M. R., Nagaraju, G. P., Zhang, C., Chen, Z., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0911 · Cited by 53
Cannabinoids Inhibited Pancreatic Cancer via P-21 Activated Kinase 1 Mediated Pathway
Yang, Y., Huynh, N. T., Dumesny, C., Wang, K., He, H. Z., & Nikfarjam, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218035 · Cited by 50
Tumor Cells and Cancer-Associated Fibroblasts: An Updated Metabolic Perspective
Gentric, G., & Mechta‐Grigoriou, F. (2021) · Cancers · doi:10.3390/cancers13030399 · Cited by 52
Sunami, Y., Boeker, V., & Kleeff, J. H. (2021) · Cancers · doi:10.3390/cancers13040697 · Cited by 56
A bird’s eye view of fibroblast heterogeneity: A pan‐disease, pan‐cancer perspective
Pradhan, R., Krishnamurty, A. T., Fletcher, A. L., Turley, S. J., & Müller, S. (2021) · Immunological Reviews · doi:10.1111/imr.12990 · Cited by 51
Zhang, B., Jin, K., Jiang, T., Wang, L., Shen, S., Luo, Z., Tuo, Y., Liu, X., Hu, Y., & Pang, Z. (2017) · Scientific Reports · doi:10.1038/s41598-017-09520-7 · Cited by 49
Immunotherapy for Pancreatic Cancer: Present and Future
Aroldi, F., & Zaniboni, A. (2017) · Immunotherapy · doi:10.2217/imt-2016-0142 · Cited by 48
Targeting stromal cell Syndecan‐2 reduces breast tumour growth, metastasis and limits immune evasion
Loftus, P., Watson, L., Deedigan, L., Camarillo‐Retamosa, E., Dwyer, R. M., O’Flynn, L., Alagesan, S., Griffin, M. D., O’Brien, T., Kerin, M. J., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33383 · Cited by 49
Ora, M., Soni, N., Nazar, A. H., Dixit, M., Singh, R., Puri, S., Graham, M. M., & Gambhir, S. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265594 · Cited by 49
Immunology of naturally transmissible tumours
Siddle, H. V. T., & Kaufman, J. (2014) · Immunology · doi:10.1111/imm.12377 · Cited by 49
Epithelial-Stromal Interactions in Pancreatic Cancer
Zhang, Y., Crawford, H. C., & di Magliano, M. P. (2018) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114515 · Cited by 52
Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer
Vonderheide, R. H., & Bear, A. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.605619 · Cited by 52
Pancreatic Fibroblast Heterogeneity: From Development to Cancer
Garcia, P. E., Scales, M. K., Allen, B. L., & di Magliano, M. P. (2020) · Cells · doi:10.3390/cells9112464 · Cited by 48
Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer
Song, N., Cui, K., Zeng, L., Li, M., Fan, Y., Shi, P., Wang, Z., Su, W., & Wang, H. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176357 · Cited by 51
Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer
Fang, B., Lu, Y., Li, X., Yu, W., Ye, D., Wei, G., & Zhu, Y. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00825-z · Cited by 49
Lu, Y., Chen, Y., Wang, Z., Shen, H.-Y., Xu, L., Huang, C., Tong, Y., Shao, Y., Zhang, H.-Q., & Fu, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06236-5 · Cited by 45
Ageing, immune fitness and cancer
Dolan, M., Libby, K. A., Ringel, A. E., van Galen, P., & McAllister, S. S. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00858-z · Cited by 55
Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer
Ali, A. I., Oliver, A. J., Samiei, T., Chan, J. D., Kershaw, M. H., & Slaney, C. Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00056 · Cited by 49
Progress in Neoantigen Targeted Cancer Immunotherapies
Han, X., Ma, X., Li, Y., Wei, Y.-Q., Peng, Y., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00728 · Cited by 49
Fotsitzoudis, C., Koulouridi, A., Messaritakis, I., Konstantinidis, T., Gouvas, N., Tsiaoussis, J., & Souglakos, J. (2022) · Cancers · doi:10.3390/cancers14184394 · Cited by 46
Timperi, E., Croizer, H., Khantakova, D., Rana, M., Molgora, M., Guerriero, J. L., Mechta-Grigoriou, F., & Romano, E. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1690 · Cited by 49
Gorchs, L., & Kaipe, H. (2021) · Cancers · doi:10.3390/cancers13122995 · Cited by 56
Extracellular Galectin 4 Drives Immune Evasion and Promotes T-cell Apoptosis in Pancreatic Cancer
Lidström, T., Cumming, J., Gaur, R., Frängsmyr, L., Pateras, I. S., Mickert, M. J., Franklin, O., Forsell, M. N. E., Arnberg, N., Dongre, M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-1088 · Cited by 47
HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation
Chia, L., Wang, B., Kim, J., Luo, L., Shuai, S., Herrera, I., Chen, S. Y., Li, L., Xian, L., Huso, T. H., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci151601 · Cited by 52
Wu, M., Wang, Y., Yang, Q., Wang, X., Yang, X., Xing, H., Sang, X., Li, X., Zhao, H., & Huo, L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265712 · Cited by 47
Cancer cachexia: molecular basis and therapeutic advances
Tan, Y., Xue, R., Pan, Y., he, Z., Hu, X., Li, Y., Li, K., Zhang, X., Bian, X.-W., & Wang, B. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02331-7 · Cited by 57
Yunger, S., El, A. B., Zeltzer, L., Fridman, E., Raviv, G., Laufer, M., Schachter, J., Markel, G., Itzhaki, O., & Besser, M. J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1672494 · Cited by 48
Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy
Anbil, S. R., Pigula, M. L., Huang, H., Mallidi, S., Broekgaarden, M., Baglo, Y., Silva, P. D., Simeone, D. M., Mino-Kenudson, M. A., Maytin, E. V., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0791 · Cited by 47
Bouzid, R., Peppelenbosch, M. P., & Buschow, S. I. (2020) · Cancers · doi:10.3390/cancers12051121 · Cited by 46
Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer
Huang, H., & Brekken, R. A. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00079.2020 · Cited by 49
Lan, C., Kitano, Y., Yamashita, Y., Yamao, T., Kajiyama, K., Yoshizumi, T., Fukuzawa, K., Sugimachi, K., Ikeda, Y., Takamori, H., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01569-6 · Cited by 47
RETRACTED ARTICLE: Hurdles to breakthrough in CAR T cell therapy of solid tumors
Marofi, F., Achmad, H., Bokov, D., Abdelbasset, W. K., Alsadoon, Z., Chupradit, S., Suksatan, W., Shariatzadeh, S., Hasanpoor, Z., Yazdanifar, M., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02819-x · Cited by 47
RetractedLi, Y., Wang, L., Ma, W., Wu, J., Wu, Q., & Sun, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06744-4 · Cited by 49
Molecular Pathways: Myeloid Complicity in Cancer
Stromnes, I. M., Greenberg, P. D., & Hingorani, S. R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0866 · Cited by 49
Role of the microenvironment in myeloid malignancies
Goulard, M., Dosquet, C., & Bonnet, D. A. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2725-4 · Cited by 49
Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
Carvalho, P. D., Machado, A. L., Martins, F., Seruca, R., & Velho, S. (2019) · Cancers · doi:10.3390/cancers11122010 · Cited by 49
Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin
Wagner, J., Wickman, E., Shaw, T. I., Anido, A. A., Langfitt, D. M., Zhang, J., Porter, S. N., Pruett‐Miller, S. M., Tillman, H. S., Krenciute, G., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0280 · Cited by 46
More than a scaffold: Stromal modulation of tumor immunity
Johansson, A., Hamzah, J., & Ganß, R. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.001 · Cited by 47
Group Young Researchers in Inflammatory Carcinogenesis, Wandmacher, A. M., Mehdorn, A., & Sebens, S. (2021) · Cancers · doi:10.3390/cancers13194932 · Cited by 48
Chen, L., Jiang, X., Li, Y., Zhang, Q., Li, Q., Zhang, X., Zhang, M., Yu, Q., & Gao, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108962 · Cited by 46
Tumor-associated fibrosis impairs the response to immunotherapy
Naik, A., & Leask, A. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.04.002 · Cited by 47
Arima, Y., Matsueda, S., & Saya, H. (2023) · Cancers · doi:10.3390/cancers15092536 · Cited by 48
Guo, J., Wang, S., & Gao, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1258538 · Cited by 47
Xu, Y., Li, W., Lin, S., Liu, B., Wu, P., & Li, L. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01204-2 · Cited by 50
Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 49
Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip
Veith, I., Nurmik, M., Mencattini, A., Damei, I., Lansche, C., Brosseau, S., Gropplero, G., Corgnac, S., Filippi, J., Poté, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101549 · Cited by 49
Cancer-Associated Fibroblasts in Pancreatic Adenocarcinoma
Pan, B., Liao, Q., Niu, Z., Zhou, L., & Zhao, Y. (2015) · Future Oncology · doi:10.2217/fon.15.176 · Cited by 45
Ren, Y. T., Zhou, X., Liu, X., Jia, H.-H., Zhao, X., Wang, Q.-X., Han, L., Song, X., Zhu, Z.-Y., Sun, T., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.003 · Cited by 45
Sorrentino, C., Miele, L., Porta, A., Pinto, A., & Morello, S. (2016) · Oncotarget · doi:10.18632/oncotarget.11729 · Cited by 45
Zhang, Q., Yang, J., Bai, J., & Ren, J. (2018) · Cancer Science · doi:10.1111/cas.13520 · Cited by 47
The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
García-Sampedro, A., Gaggia, G., Ney, A., Mahamed, I., & Acedo, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040566 · Cited by 47
Tailor‐Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma
Hu, X., Xia, F., Lee, J., Li, F., Lu, X., Zhuo, X., Nie, G., & Ling, D. (2021) · Advanced Science · doi:10.1002/advs.202002545 · Cited by 46
Natoli, M., Herzig, P., Bejestani, E. P., Buchi, M., Ritschard, R., Lloyd, G. K., Mohanlal, R. W., Tonra, J. R., Huang, L., Heinzelmann, V., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644608 · Cited by 45
O’Connor, R. A., Chauhan, V., Mathieson, L., Titmarsh, H. F., Koppensteiner, L., Young, I., Tagliavini, G., Dorward, D. A., Prost, S., Dhaliwal, K., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1940675 · Cited by 46
Radiation Damage to Tumor Vasculature Initiates a Program That Promotes Tumor Recurrences
Brown, J. M. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.05.028 · Cited by 47
Chen, X., Liu, Y., Wang, Y., Wang, C., Chen, X., Xiong, Y., Liu, L., Yuan, X., Tang, H., Shu, C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4029 · Cited by 45
The Role of the Microbiome in Pancreatic Cancer
Miyabayashi, K., Ijichi, H., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184479 · Cited by 48
Mazzaglia, C., Sheng, Y., Rodrigues, L. N., Lei, I. M., Shields, J. D., & Huang, Y. Y. S. (2023) · Biofabrication · doi:10.1088/1758-5090/acb1db · Cited by 47
Lü, L., Gao, Y., Huang, D., Liu, H., Yin, D., Li, M., Zheng, J., Wang, S., Wu, W., Zhao, L., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007447 · Cited by 43
Yang, D., Sun, X., Moniruzzaman, R., Wang, H., Citu, C., Zhao, Z., Wistuba, I. I., Wang, H., Maitra, A., & Chen, Y. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.03.007 · Cited by 44
Dziadek, S., Kraxner, A., Cheng, W., Yang, T.-H. O., Flores, M., Theiss, N., Tsao, T., Andersson, E. K., Harring, S. V., Bröske, A.-M. E., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1352615 · Cited by 44
Immunotherapy for pancreatic cancer: A long and hopeful journey
Xu, J., Wang, L., Cheng, Y., Zhang, G., Hu, S., Zhou, B., & Zhan, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.03.040 · Cited by 45
Choueiri, T. K., Atkins, M. B., Rose, T. L., Alter, R. S., Ju, Y., Niland, K., Wang, Y., Arbeit, R. D., Parasuraman, S., Gan, L., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-01058-2 · Cited by 49
Zhang, L., Cascio, S., Mellors, J. W., Buckanovich, R. J., & Osmanbeyoglu, H. U. (2024) · Communications Biology · doi:10.1038/s42003-023-05733-x · Cited by 44
Immune Therapy in GI Malignancies: A Review
Wang, J., Reiss, K. A., Khatri, R. G., Jaffee, E. M., & Laheru, D. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.7879 · Cited by 43
Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC
Strell, C., Norberg, K. J., Mezheyeuski, A., Schnittert, J., Kuninty, P. R., Moro, C. F., Paulsson, J., Schultz, N. A., Calatayud, D., Löhr, M. J., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.140 · Cited by 43
Obstacles to T cell migration in the tumor microenvironment
Nicolás‐Boluda, A., & Donnadieu, E. (2018) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2018.12.006 · Cited by 45
Cellini, F., ARCELLI, A., Simoni, N., Caravatta, L., Buwenge, M., Calabrese, A., Brunetti, O., Genovesi, D., Mazzarotto, R., Deodato, F., et al. (2020) · Cancers · doi:10.3390/cancers12071729 · Cited by 43
Senescence and Immunoregulation in the Tumor Microenvironment
Ruhland, M. K., & Alspach, E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.754069 · Cited by 45
Harryvan, T. J., Visser, M., de Bruin, L., Plug, L. G., Griffioen, L., Mulder, A., van Veelen, P. A., van Noort, G. J. V. D. H., Jongsma, M. L. M., Meeuwsen, M. H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003591 · Cited by 44
Metadata
- Authors
- Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., Teichmann, S. A., Janowitz, T., Jodrell, D. I., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- MRC Laboratory of Molecular Biology (GB)
- Johns Hopkins University (US)
- Ludwig Collaborative Laboratory, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231; and
- European Bioinformatics Institute (GB)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-11-25
- Volume
- 110
- Issue
- 50
- Pages
- 20212-20217
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3864274
- OpenAlex
- W2086834665
- Cited by
- 2,100
- References
- 28
- Citations by year
- 2026: 252 · 2025: 157 · 2024: 226 · 2023: 214 · 2022: 221 · 2021: 244 · 2020: 203 · 2019: 149 · 2018: 125 · 2017: 119 · 2016: 95 · 2015: 63 · 2014: 30
- FWCI
- 33.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK (15678)
- National Institute for Health and Care Research (CL-2011-14-007)
- Medical Research Council (MC_PC_12012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- pancreatic ductal adenocarcinoma, CXCL12, fibroblast activation protein, cancer-associated fibroblasts, PD-L1 blockade, CTLA-4 blockade, tumor immune evasion, tumor stroma, CXCR4 inhibition, AMD3100, CD8+ T cells, chemokine signaling, immunotherapy resistance
- MeSH terms
- Cyclams, Fibroblast Activation Protein Alpha, Analysis of Variance, Animals, Base Sequence, Benzylamines, Fibroblasts, Flow Cytometry, Fluorescent Antibody Technique, Heterocyclic Compounds, Immunohistochemistry, Immunotherapy, Membrane Proteins, Molecular Sequence Data, Pancreatic Neoplasms, Endopeptidases, Serine Endopeptidases, Sequence Analysis, RNA, Gelatinases, Tumor Escape, Carcinoma, Pancreatic Ductal, Mice, Chemokine CXCL12, Enzyme-Linked Immunospot Assay
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
